Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $478000.0.

  • Xeris Biopharma Holdings' Gains from Investment Securities rose 47590.36% to $478000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 5805.04%. This contributed to the annual value of $3.7 million for FY2024, which is 8137.01% down from last year.
  • Xeris Biopharma Holdings' Gains from Investment Securities amounted to $478000.0 in Q3 2025, which was up 47590.36% from $860000.0 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Gains from Investment Securities registered a high of $20.0 million during Q2 2023, and its lowest value of -$81000.0 during Q3 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $416000.0 (2022), whereas its average is $3.6 million.
  • In the last 5 years, Xeris Biopharma Holdings' Gains from Investment Securities tumbled by 15062.5% in 2021 and then soared by 9077142.86% in 2023.
  • Xeris Biopharma Holdings' Gains from Investment Securities (Quarter) stood at $169000.0 in 2021, then tumbled by 87.57% to $21000.0 in 2022, then surged by 90771.43% to $19.1 million in 2023, then tumbled by 99.13% to $166000.0 in 2024, then surged by 187.95% to $478000.0 in 2025.
  • Its Gains from Investment Securities stands at $478000.0 for Q3 2025, versus $860000.0 for Q2 2025 and $8.0 million for Q1 2025.